US Bancorp DE purchased a new stake in Vaxart, Inc. (NASDAQ:VXRT) during the second quarter, Holdings Channel.com reports. The firm purchased 10,000 shares of the biotechnology company’s stock, valued at approximately $75,000.
Other hedge funds have also made changes to their positions in the company. Sowell Financial Services LLC lifted its holdings in shares of Vaxart by 1,194.8% in the 1st quarter. Sowell Financial Services LLC now owns 5,179 shares of the biotechnology company’s stock valued at $36,000 after buying an additional 4,779 shares during the period. BNP Paribas Arbitrage SA raised its holdings in shares of Vaxart by 32.4% during the first quarter. BNP Paribas Arbitrage SA now owns 7,383 shares of the biotechnology company’s stock valued at $45,000 after acquiring an additional 1,805 shares during the last quarter. Teacher Retirement System of Texas acquired a new position in shares of Vaxart during the first quarter valued at approximately $68,000. Kestra Private Wealth Services LLC acquired a new position in shares of Vaxart during the first quarter valued at approximately $79,000. Finally, GSA Capital Partners LLP raised its holdings in shares of Vaxart by 86.2% during the first quarter. GSA Capital Partners LLP now owns 19,310 shares of the biotechnology company’s stock valued at $117,000 after acquiring an additional 8,939 shares during the last quarter. Hedge funds and other institutional investors own 28.32% of the company’s stock.
VXRT stock opened at $7.87 on Tuesday. The business has a 50 day simple moving average of $8.39 and a 200-day simple moving average of $7.41. The firm has a market capitalization of $966.58 million, a PE ratio of -16.40 and a beta of 0.31. Vaxart, Inc. has a 1 year low of $3.50 and a 1 year high of $24.90.
In related news, SVP Sean Tucker sold 4,172 shares of the stock in a transaction that occurred on Tuesday, August 10th. The stock was sold at an average price of $10.20, for a total value of $42,554.40. Following the completion of the transaction, the senior vice president now directly owns 333 shares in the company, valued at $3,396.60. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Insiders sold 7,773 shares of company stock valued at $73,344 over the last quarter. 3.10% of the stock is currently owned by company insiders.
A number of equities analysts have commented on VXRT shares. B. Riley cut Vaxart from a “buy” rating to a “neutral” rating and reduced their target price for the company from $13.00 to $9.00 in a report on Tuesday, June 29th. Zacks Investment Research cut Vaxart from a “buy” rating to a “hold” rating in a report on Thursday, September 2nd. Piper Sandler started coverage on Vaxart in a report on Friday, June 11th. They set an “overweight” rating and a $18.00 target price for the company. Finally, Jefferies Financial Group began coverage on Vaxart in a report on Thursday, June 24th. They set a “buy” rating and a $13.00 target price for the company.
Vaxart Company Profile
Vaxart, Inc operates as a clinical-stage biotechnology company, which engages in the development of oral recombinant vaccines. Its products include Influenza, Norovirus and Respiratory Syncytial Virus. The company was founded in 2004 and is headquartered in South San Francisco, CA.
See Also: What Are Cryptocurrencies?
Want to see what other hedge funds are holding VXRT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Vaxart, Inc. (NASDAQ:VXRT).
Receive News & Ratings for Vaxart Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vaxart and related companies with MarketBeat.com's FREE daily email newsletter.